What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today
After the company announced it has filed for approval with New Zealand regulators to begin phase 1 studies of its hepatitis B RNAi therapy, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shot 10.5% higher at 3:30 p.m. EST Friday.
Arrowhead Pharmaceuticals was forced to abandon all of its clinical-stage therapies in 2016 following regulators' concerns over liver toxicity. The news devastated shares and forced the company back to the drawing board to develop a new RNA delivery system.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Arrowhead Pharmaceuticals Inc. Aktie
20,60 €
-1,15 %
Leichte Buy-Präferenz bei der Arrowhead Pharmaceuticals Inc. Aktie.
Die Community erwartet für Arrowhead Pharmaceuticals Inc. ein Kursziel von 55 €, was den aktuellen Kurs von 20.6 € mehr als verdoppeln würde.
